# A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

> **NCT04504032** · PHASE2 · TERMINATED · sponsor: **Gates Medical Research Institute** · enrollment: 497 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04504032
- **Lead sponsor:** Gates Medical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-02
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-29
- **Target enrollment:** 497 (ACTUAL)
- **Why stopped:** Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504032, "A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04504032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*